Damora Therapeutics (DMRA) Cash from Financing Activities (2020 - 2026)

Damora Therapeutics has reported Cash from Financing Activities for 4 years, with the latest figure at $295.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $295.9 million; the trailing twelve-month figure through Mar 2026 stood at $298.8 million (changed N/A YoY), and the FY2025 full-year result was $266.8 million, changed N/A from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $295.9 million, up from $171000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $295.9 million in Q1 2026, with the low at $23000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $49.9 million across 3 years, with a median of $297500.0 in 2022.
• The largest YoY upside for Cash from Financing Activities was 59.67% in 2023 against a maximum downside of 59.67% in 2023.
• Damora Therapeutics' Cash from Financing Activities stood at $65000.0 in 2022, then jumped by 163.08% to $171000.0 in 2023, then soared by 172953.22% to $295.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $295.9 million (Q1 2026), $171000.0 (Q3 2023), and $2.7 million (Q2 2023), per Business Quant data.